CEO Tehila Ben-Moshe (Biond Biologics)
January 12, 2021 08:15 AM ESTUpdated 09:41 AM
Deals

Dou­bling down on on­col­o­gy, Sanofi buys in­to a new check­point in­hibitor with a $125M down pay­ment

Nicole DeFeudis

Editor

On its lat­est shop­ping trip through the im­muno-on­col­o­gy de­part­ment, Sanofi picked up the rights to a check­point in­hibitor from Biond Bi­o­log­ics’ pipeline, pay­ing over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times